Research Analysts Offer Predictions for ANI Pharmaceuticals, Inc.’s Q3 2024 Earnings (NASDAQ:ANIP)

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) – Research analysts at HC Wainwright dropped their Q3 2024 earnings per share estimates for shares of ANI Pharmaceuticals in a research report issued on Wednesday, June 26th. HC Wainwright analyst O. Livnat now anticipates that the specialty pharmaceutical company will post earnings per share of $0.75 for the quarter, down from their prior estimate of $0.82. HC Wainwright has a “Buy” rating and a $94.00 price objective on the stock. The consensus estimate for ANI Pharmaceuticals’ current full-year earnings is $3.34 per share. HC Wainwright also issued estimates for ANI Pharmaceuticals’ FY2024 earnings at $3.34 EPS.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings data on Friday, May 10th. The specialty pharmaceutical company reported $0.95 earnings per share for the quarter, beating analysts’ consensus estimates of $0.79 by $0.16. ANI Pharmaceuticals had a return on equity of 17.15% and a net margin of 6.87%. The company had revenue of $137.43 million for the quarter, compared to analyst estimates of $125.01 million.

A number of other analysts also recently issued reports on the company. Guggenheim reaffirmed a “buy” rating and issued a $77.00 target price on shares of ANI Pharmaceuticals in a research note on Tuesday, April 23rd. Capital One Financial began coverage on ANI Pharmaceuticals in a research note on Friday, March 15th. They issued an “overweight” rating and a $80.00 target price for the company. Finally, Truist Financial raised their target price on ANI Pharmaceuticals from $72.00 to $80.00 and gave the stock a “buy” rating in a research note on Friday, March 1st. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $82.75.

ANI Pharmaceuticals Stock Up 2.0 %

Shares of ANIP opened at $65.49 on Thursday. ANI Pharmaceuticals has a 52-week low of $48.20 and a 52-week high of $70.81. The company has a market capitalization of $1.37 billion, a PE ratio of 40.93 and a beta of 0.81. The stock has a fifty day simple moving average of $64.28 and a two-hundred day simple moving average of $61.59. The company has a quick ratio of 3.12, a current ratio of 3.95 and a debt-to-equity ratio of 0.63.

Insider Buying and Selling

In related news, Director Renee P. Tannenbaum sold 2,000 shares of the firm’s stock in a transaction dated Thursday, May 16th. The stock was sold at an average price of $63.87, for a total transaction of $127,740.00. Following the completion of the sale, the director now directly owns 18,211 shares of the company’s stock, valued at approximately $1,163,136.57. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other ANI Pharmaceuticals news, Director Renee P. Tannenbaum sold 2,000 shares of ANI Pharmaceuticals stock in a transaction dated Thursday, May 16th. The stock was sold at an average price of $63.87, for a total value of $127,740.00. Following the completion of the transaction, the director now directly owns 18,211 shares of the company’s stock, valued at approximately $1,163,136.57. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO Stephen P. Carey sold 5,000 shares of ANI Pharmaceuticals stock in a transaction dated Tuesday, June 4th. The shares were sold at an average price of $63.58, for a total value of $317,900.00. Following the completion of the transaction, the chief financial officer now directly owns 161,968 shares of the company’s stock, valued at $10,297,925.44. The disclosure for this sale can be found here. In the last ninety days, insiders sold 176,688 shares of company stock valued at $11,408,863. 12.70% of the stock is currently owned by insiders.

Hedge Funds Weigh In On ANI Pharmaceuticals

Institutional investors have recently bought and sold shares of the company. Pacer Advisors Inc. acquired a new position in ANI Pharmaceuticals in the 4th quarter valued at about $41,000. AJOVista LLC purchased a new position in shares of ANI Pharmaceuticals in the 4th quarter valued at about $58,000. SG Americas Securities LLC purchased a new position in shares of ANI Pharmaceuticals in the 1st quarter valued at about $106,000. China Universal Asset Management Co. Ltd. boosted its stake in shares of ANI Pharmaceuticals by 361.4% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 2,367 shares of the specialty pharmaceutical company’s stock valued at $131,000 after buying an additional 1,854 shares during the period. Finally, ADAR1 Capital Management LLC purchased a new position in shares of ANI Pharmaceuticals in the 4th quarter valued at about $132,000. 76.05% of the stock is owned by institutional investors and hedge funds.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.